Auszug aus dem SEC report von Anfang April:
The Company has not paid any dividends on the Common Stock since its inception and does not contemplate paying dividends on the Common Stock in the foreseeable future.
Basic and diluted loss per share (.25) (.71)
The Company has experienced significant operating losses since its inception. The Company received FDA approval in 1989 to market ALFERON N Injection in the United States for the treatment of certain genital warts. ALFERON N Injection is currently marketed and sold in the United States by the Company and in Mexico and Germany by licensees. However, the Company has had limited revenues from the sale of ALFERON N Injection to date. For the Company to operate profitably, the Company must sell significantly more ALFERON N Injection.
Und was ist mit den Schulden an das Rote Kreuz? As of November 23, 1998, the Company owed the Red Cross approximately $1.46 million plus interest at the rate of 6% annum accruing from April 1, 1998 (the "Red Cross Liability") for white blood cells purchased pursuant to the Supply Agreement.
In an agreement dated November 23, 1998, the Company agreed to grant the Red Cross a security interest in certain assets to secure the Red Cross Liability and to issue to the Red Cross 300,000 shares of Common Stock (with a market value of $1,171,875 at December 4, 1998) and additional shares at some future date as requested by the Red Cross to satisfy any remaining amount of the Red Cross Liability.
Offenbar ist man jetzt bemüht,das Spektrum zu erweitern,aber mit einer Firma,die in der Krebsforschung engagiert ist-Metacine-gegründet von Forschern der Pittsburgh University.
|
Thread abonnieren
